Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.
Groothuis, J R
Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. [electronic resource] - Antimicrobial agents and chemotherapy Mar 1995 - 668-71 p. digital
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0066-4804
10.1128/AAC.39.3.668 doi
Double-Blind Method
Half-Life
Humans
Immunoglobulins--adverse effects
Infant
Infant, Newborn
Infant, Premature
Prospective Studies
Respiratory Syncytial Virus Infections--prevention & control
Respiratory Syncytial Virus, Human--immunology
Therapeutic Equivalency
Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. [electronic resource] - Antimicrobial agents and chemotherapy Mar 1995 - 668-71 p. digital
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0066-4804
10.1128/AAC.39.3.668 doi
Double-Blind Method
Half-Life
Humans
Immunoglobulins--adverse effects
Infant
Infant, Newborn
Infant, Premature
Prospective Studies
Respiratory Syncytial Virus Infections--prevention & control
Respiratory Syncytial Virus, Human--immunology
Therapeutic Equivalency